{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:37Z","timestamp":1791323677660,"version":"4.3.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22367012"],"award-info":[{"award-number":["22367012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Jiangxi Province, China","award":["20232ACB206060"],"award-info":[{"award-number":["20232ACB206060"]}]},{"name":"the Natural Science Foundation of Jiangxi Province, China","award":["2024BAB23092"],"award-info":[{"award-number":["2024BAB23092"]}]},{"name":"the Doctoral Research Startup Fund of Jiangxi Normal University of Science and Technology","award":["2023BSQD41"],"award-info":[{"award-number":["2023BSQD41"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paclitaxel (PTX) serves as a first-line chemotherapeutic agent for the treatment of advanced non-small cell lung cancer (NSCLC). However, the emergence of drug resistance poses a significant threat to patient survival. The serine synthetic pathway (SSP) has been implicated in drug resistance across various cancers and is notably activated in NSCLC. Nevertheless, its role in PTX resistance remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we investigated the influence of the SSP on PTX resistance in NSCLC and explored a novel combination therapeutic strategy involving PTX and anlotinib to reverse NSCLC drug resistance. Specifically, using integrated transcriptomic and metabolomic analyses along with\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      experimental approaches, we aimed to elucidate the regulatory role of activated SSP in PTX resistance and to determine whether the combination of anlotinib and PTX can overcome PTX resistance in NSCLC through modulation of the SSP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that SSP activation drives PTX resistance by promoting the proliferation of PTX-resistant NSCLC cells, increasing the expression and transport function of P-glycoprotein (P-gp), inducing epithelial-to-mesenchymal transition (EMT), and maintaining redox homeostasis. Anlotinib synergizes with PTX by suppressing SSP. This leads to attenuated glycolysis, disruption of the AKT\/ERK proliferative signaling pathway, inhibition of P-gp expression and function, reversal of EMT, and redox imbalance, which subsequently elevates reactive oxygen species (ROS) levels and activates the mitochondrial apoptosis pathway, ultimately inducing apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Collectively, our study demonstrates that anlotinib combined with PTX, via SSP inhibition, is a promising strategy for overcoming PTX resistance in NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03627-w","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:12:38Z","timestamp":1767633158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib"],"prefix":"10.1186","volume":"45","author":[{"given":"Mengting","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wufu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"9","key":"3627_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Reviews Clin Oncol. 2023;20(9):624\u201339.","journal-title":"Nat Reviews Clin Oncol"},{"key":"3627_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.omtn.2019.06.017","volume":"17","author":"W Liu","year":"2019","unstructured":"Liu W, Lo YL, Hsu C, Wu YT, Liao ZX, Wu WJ, et al. CS-PEI\/Beclin-siRNA downregulate multidrug resistance proteins and increase Paclitaxel therapeutic efficacy against NSCLC. Mol Therapy Nucleic Acids. 2019;17:477\u201390.","journal-title":"Mol Therapy Nucleic Acids"},{"issue":"1","key":"3627_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-022-01579-9","volume":"21","author":"W Wang","year":"2022","unstructured":"Wang W, Wang J, Liu S, Ren Y, Wang J, Liu S, et al. An EHMT2\/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate Paclitaxel resistance in lung cancer. Mol Cancer. 2022;21(1):106.","journal-title":"Mol Cancer"},{"key":"3627_CR4","doi-asserted-by":"publisher","first-page":"100754","DOI":"10.1016\/j.drup.2021.100754","volume":"55","author":"T Das","year":"2021","unstructured":"Das T, Anand U, Pandey SK, Ashby CR, Assaraf YG, Chen Z-S, et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updates. 2021;55:100754.","journal-title":"Drug Resist Updates"},{"key":"3627_CR5","doi-asserted-by":"publisher","first-page":"101011","DOI":"10.1016\/j.drup.2023.101011","volume":"71","author":"C-P Wu","year":"2023","unstructured":"Wu C-P, Hsiao S-H, Wu Y-S. Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2. Drug Resist Updates. 2023;71:101011.","journal-title":"Drug Resist Updates"},{"key":"3627_CR6","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.drup.2025.101223","volume":"81","author":"GL Beretta","year":"2025","unstructured":"Beretta GL, Cassinelli G, Rossi G, Azzariti A, Corbeau I, Tosi D, et al. Novel insights into taxane pharmacology: an update on drug resistance mechanisms, Immunomodulation and drug delivery strategies. Drug Resist Updates. 2025;81:101223.","journal-title":"Drug Resist Updates"},{"key":"3627_CR7","doi-asserted-by":"publisher","first-page":"100881","DOI":"10.1016\/j.drup.2022.100881","volume":"65","author":"ER Smith","year":"2022","unstructured":"Smith ER, Wang J-Q, Yang D-H, Xu X-X. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updates. 2022;65:100881.","journal-title":"Drug Resist Updates"},{"key":"3627_CR8","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.drup.2021.100797","volume":"59","author":"AC Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves AC, Richiardone E, Jorge J, Pol\u00f3nia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance \u2013 Clinical implications. Drug Resist Updates. 2021;59:100797.","journal-title":"Drug Resist Updates"},{"issue":"5","key":"3627_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.molcel.2019.08.028","volume":"76","author":"PH Chen","year":"2019","unstructured":"Chen PH, Cai L, Huffman K, Yang C, Kim J, Faubert B, et al. Metabolic diversity in human Non-Small cell lung cancer cells. Mol Cell. 2019;76(5):838\u2013e851835.","journal-title":"Mol Cell"},{"issue":"6","key":"3627_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.tem.2023.03.001","volume":"34","author":"L He","year":"2023","unstructured":"He L, Ding Y, Zhou X, Li T, Yin Y. Serine signaling governs metabolic homeostasis and health. Trends Endocrinol Metabolism. 2023;34(6):361\u201372.","journal-title":"Trends Endocrinol Metabolism"},{"issue":"6","key":"3627_CR11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.cmet.2019.02.015","volume":"29","author":"MR Sullivan","year":"2019","unstructured":"Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, et al. Increased Serine synthesis provides an advantage for tumors arising in tissues where Serine levels are limiting. Cell Metabol. 2019;29(6):1410\u2013e14211414.","journal-title":"Cell Metabol"},{"issue":"2","key":"3627_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42255-020-00329-9","volume":"3","author":"SL Geeraerts","year":"2021","unstructured":"Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR. The Ins and outs of Serine and Glycine metabolism in cancer. Nat Metabolism. 2021;3(2):131\u201341.","journal-title":"Nat Metabolism"},{"issue":"1","key":"3627_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41467-020-20223-y","volume":"12","author":"M Tajan","year":"2021","unstructured":"Tajan M, Hennequart M, Cheung EC, Zani F, Hock AK, Legrave N, et al. Serine synthesis pathway Inhibition cooperates with dietary Serine and Glycine limitation for cancer therapy. Nat Commun. 2021;12(1):366.","journal-title":"Nat Commun"},{"issue":"7","key":"3627_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s42255-024-01066-z","volume":"6","author":"HM Lee","year":"2024","unstructured":"Lee HM, Muhammad N, Lieu EL, Cai F, Mu J, Ha Y-S, et al. Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. Nat Metabolism. 2024;6(7):1310\u201328.","journal-title":"Nat Metabolism"},{"issue":"7","key":"3627_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Hu B, Cheng J-W, Sun Y-F, Zhou K-Q, Wang P-X, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11(7):573.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3627_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120.","journal-title":"J Hematol Oncol"},{"key":"3627_CR17","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.2147\/CMAR.S246000","volume":"12","author":"K Zhang","year":"2020","unstructured":"Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S, et al. Efficacy and safety of anlotinib in advanced Non-Small cell lung cancer: A Real-World study. Cancer Manag Res. 2020;12:3409\u201317.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"3627_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12967-022-03451-2","volume":"20","author":"S Wang","year":"2022","unstructured":"Wang S, Lou N, Luo R, Hao X, Liu Y, Wang L, et al. Role of chemokine-mediated angiogenesis in resistance towards Crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC. J Translational Med. 2022;20(1):248.","journal-title":"J Translational Med"},{"issue":"1","key":"3627_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-024-01927-9","volume":"9","author":"H-Q Zhou","year":"2024","unstructured":"Zhou H-Q, Zhang Y-X, Chen G, Yu Q-T, Zhang H, Wu G-W, et al. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial. Signal Transduct Target Therapy. 2024;9(1):215.","journal-title":"Signal Transduct Target Therapy"},{"key":"3627_CR20","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.phrs.2023.106668","volume":"188","author":"T Lei","year":"2023","unstructured":"Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C, et al. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis. Pharmacol Res. 2023;188:106668.","journal-title":"Pharmacol Res"},{"key":"3627_CR21","doi-asserted-by":"publisher","first-page":"113537","DOI":"10.1016\/j.biopha.2022.113537","volume":"155","author":"S Xu","year":"2022","unstructured":"Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, et al. XS-2, a novel potent dual PI3K\/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer. Biomed Pharmacother. 2022;155:113537.","journal-title":"Biomed Pharmacother"},{"key":"3627_CR22","doi-asserted-by":"publisher","first-page":"1084609","DOI":"10.3389\/fgene.2022.1084609","volume":"13","author":"X Zhou","year":"2023","unstructured":"Zhou X, Tian C, Cao Y, Zhao M, Wang K. The role of Serine metabolism in lung cancer: from oncogenesis to tumor treatment. Front Genet. 2023;13:1084609.","journal-title":"Front Genet"},{"issue":"1","key":"3627_CR23","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"L Wei","year":"2019","unstructured":"Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, et al. Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10(1):4681.","journal-title":"Nat Commun"},{"issue":"6","key":"3627_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nchembio.2070","volume":"12","author":"ME Pacold","year":"2016","unstructured":"Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, et al. A PHGDH inhibitor reveals coordination of Serine synthesis and one-carbon unit fate. Nat Chem Biol. 2016;12(6):452\u20138.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"3627_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2023.01.010","volume":"35","author":"D Zhang","year":"2023","unstructured":"Zhang D, Li AM, Hu G, Huang M, Yang F, Zhang L, et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metabol. 2023;35(3):517\u2013e534518.","journal-title":"Cell Metabol"},{"issue":"6","key":"3627_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cmet.2013.11.004","volume":"18","author":"J Ding","year":"2013","unstructured":"Ding J, Li T, Wang X, Zhao E, Choi J-H, Yang L, et al. The histone H3 methyltransferase G9A epigenetically activates the Serine-Glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metabol. 2013;18(6):896\u2013907.","journal-title":"Cell Metabol"},{"issue":"6","key":"3627_CR27","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cmet.2019.09.014","volume":"30","author":"K Huang","year":"2019","unstructured":"Huang K, Liang Q, Zhou Y, Jiang L-l, Gu W-m, Luo M-y, et al. A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of Non-Small-Cell lung cancer. Cell Metabol. 2019;30(6):1107\u2013e11191108.","journal-title":"Cell Metabol"},{"issue":"1","key":"3627_CR28","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1038\/s41467-024-49667-2","volume":"15","author":"L Yu","year":"2024","unstructured":"Yu L, Deng Y, Wang X, Santos C, Davis IJ, Earp HS, et al. Co-targeting JAK1\/STAT6\/GAS6\/TAM signaling improves chemotherapy efficacy in ewing sarcoma. Nat Commun. 2024;15(1):5292.","journal-title":"Nat Commun"},{"issue":"1","key":"3627_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, Tigu A-B, Munteanu R, Moldovan C-S, Kegyes D, Onaciu A, et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Therapy. 2024;9(1):201.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"3627_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","volume":"38","author":"L Jiang","year":"2019","unstructured":"Jiang L, Wang P, Sun Y-J, Wu Y-J. Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway. J Experimental Clin Cancer Res. 2019;38(1):265.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3627_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejpb.2015.11.019","volume":"100","author":"K Netsomboon","year":"2016","unstructured":"Netsomboon K, Laffleur F, Suchaoin W, Bernkop-Schn\u00fcrch A. Novel in vitro transport method for screening the reversibility of P-glycoprotein inhibitors. Eur J Pharm Biopharm. 2016;100:9\u201314.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3627_CR32","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1038\/s41467-022-30362-z","volume":"13","author":"MH Soflaee","year":"2022","unstructured":"Soflaee MH, Kesavan R, Sahu U, Tasdogan A, Villa E, Djabari Z, et al. Purine nucleotide depletion prompts cell migration by stimulating the Serine synthesis pathway. Nat Commun. 2022;13(1):2698.","journal-title":"Nat Commun"},{"issue":"8","key":"3627_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discovery. 2024;23(8):583\u2013606.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"3627_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41420-021-00453-9","volume":"7","author":"O Wattanathamsan","year":"2021","unstructured":"Wattanathamsan O, Thararattanobon R, Rodsiri R, Chanvorachote P, Vinayanuwattikun C, Pongrakhananon V. Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization. Cell Death Discovery. 2021;7(1):67.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"3627_CR35","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1038\/s41467-025-58966-1","volume":"16","author":"F Huang","year":"2025","unstructured":"Huang F, Wang Y, Zhang X, Gao W, Li J, Yang Y, et al. m6A\/IGF2BP3-driven Serine biosynthesis fuels AML stemness and metabolic vulnerability. Nat Commun. 2025;16(1):4214.","journal-title":"Nat Commun"},{"issue":"6","key":"3627_CR36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/cancers13061191","volume":"13","author":"A S\u00e1nchez-Castillo","year":"2021","unstructured":"S\u00e1nchez-Castillo A, Vooijs M, Kampen KR. Linking Serine\/Glycine metabolism to radiotherapy resistance. Cancers (Basel). 2021;13(6):1191.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3627_CR37","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.7150\/thno.23177","volume":"8","author":"JK Dong","year":"2018","unstructured":"Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, et al. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase. Theranostics. 2018;8(7):1808\u201323.","journal-title":"Theranostics"},{"issue":"19","key":"3627_CR38","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-21-4074","volume":"82","author":"MY Luo","year":"2022","unstructured":"Luo MY, Zhou Y, Gu WM, Wang C, Shen NX, Dong JK, et al. Metabolic and nonmetabolic functions of PSAT1 coordinate signaling cascades to confer EGFR inhibitor resistance and drive progression in lung adenocarcinoma. Cancer Res. 2022;82(19):3516\u201331.","journal-title":"Cancer Res"},{"issue":"8","key":"3627_CR39","first-page":"604","volume":"42","author":"SM Park","year":"2019","unstructured":"Park SM, Seo EH, Bae DH, Kim SS, Kim J, Lin W, et al. Phosphoserine phosphatase promotes lung cancer progression through the dephosphorylation of IRS-1 and a noncanonical L-Serine-Independent pathway. Mol Cells. 2019;42(8):604\u201316.","journal-title":"Mol Cells"},{"issue":"1","key":"3627_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","volume":"38","author":"L Liang","year":"2019","unstructured":"Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy Inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. J Experimental Clin Cancer Res. 2019;38(1):71.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"9","key":"3627_CR41","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41419-020-02938-4","volume":"11","author":"L Yang","year":"2020","unstructured":"Yang L, Zhou X, Sun J, Lei Q, Wang Q, Pan D, et al. Reactive oxygen species mediate anlotinib-induced apoptosis via activation of Endoplasmic reticulum stress in pancreatic cancer. Cell Death Dis. 2020;11(9):766.","journal-title":"Cell Death Dis"},{"issue":"7","key":"3627_CR42","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.7150\/jca.45618","volume":"12","author":"LH Yan","year":"2021","unstructured":"Yan LH, Zhang D, Mo SS, Yuan H, Mo XW, Zhao JM. Anlotinib suppresses metastasis and multidrug resistance via dual Blockade of MET\/ABCB1 in colorectal carcinoma cells. J Cancer. 2021;12(7):2092\u2013104.","journal-title":"J Cancer"},{"issue":"11","key":"3627_CR43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a Third-Line or further treatment on overall survival of patients with advanced Non-Small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569\u201375.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3627_CR44","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302. Br J Cancer. 2018;118(5):654\u201361.","journal-title":"Br J Cancer"},{"issue":"7","key":"3627_CR45","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00432-021-03752-x","volume":"148","author":"F Wang","year":"2022","unstructured":"Wang F, Jin F, Cheng B, Zhang Y, Zhou Q, Wang S. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2022;148(7):1721\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"3627_CR46","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.21037\/tlcr-22-438","volume":"11","author":"T Chu","year":"2022","unstructured":"Chu T, Zhang W, Zhang B, Zhong R, Zhang X, Gu A, et al. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Transl Lung Cancer Res. 2022;11(7):1394\u2013404.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"3627_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3892\/ol.2024.14746","volume":"28","author":"H Xu","year":"2024","unstructured":"Xu H, Liang Y, Tang W, Yang X, Du X. Efficacy and safety of anlotinib combined with S\u20131 as a third\u2013 or later\u2013line treatment for advanced non\u2013small cell lung cancer in china: A systematic review and meta\u2013analysis. Oncol Lett. 2024;28(6):613.","journal-title":"Oncol Lett"},{"key":"3627_CR48","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.2147\/CMAR.S319650","volume":"13","author":"Z He","year":"2021","unstructured":"He Z, Liu J, Ma Y, Jiang H, Cui Z, Wang G, et al. Anlotinib combined with cranial radiotherapy for Non-Small cell lung cancer patients with brain metastasis: A Retrospectively, control study. Cancer Manag Res. 2021;13:6101\u201311.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"3627_CR49","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b study of sintilimab plus anlotinib as First-line therapy in patients with advanced NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(4):643\u201352.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"3627_CR50","doi-asserted-by":"publisher","first-page":"e21055","DOI":"10.1200\/JCO.2021.39.15_suppl.e21055","volume":"39","author":"Y Fang","year":"2021","unstructured":"Fang Y, Pan H, Shou J, Hong W, Guo Q, Yang X, et al. Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): updated results from a phase I\/II study. J Clin Oncol. 2021;39:e21055\u201321055. (15_suppl).","journal-title":"J Clin Oncol"},{"issue":"3","key":"3627_CR51","doi-asserted-by":"publisher","first-page":"S596","DOI":"10.1016\/j.jtho.2021.01.1081","volume":"16","author":"L Wu","year":"2021","unstructured":"Wu L, Wu Z, Xiao Z, Weng J, Xiao M, Ma Z, et al. P76.24 A randomized phase 2 trial of anlotinib plus docetaxel vs docetaxel as 2nd-Line therapy for EGFR-Negative NSCLC (ALTER-L018). J Thorac Oncol. 2021;16(3):S596.","journal-title":"J Thorac Oncol"},{"key":"3627_CR52","doi-asserted-by":"publisher","first-page":"S877","DOI":"10.1016\/j.annonc.2020.08.1690","volume":"31","author":"X Chen","year":"2020","unstructured":"Chen X, Shen J, Li X, Yang S, Xia B, Wang B, et al. Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial. Ann Oncol. 2020;31:S877\u2013877.","journal-title":"Ann Oncol"},{"issue":"5","key":"3627_CR53","first-page":"1050","volume":"14","author":"W Shunxi","year":"2023","unstructured":"Shunxi W, Xiaoxue Y, Guanbin S, Li Y, Junyu J, Wanqian L. Serine metabolic reprogramming in tumorigenesis, tumor Immunity, and clinical Treatment, advances in nutrition (Bethesda. Md). 2023;14(5):1050\u201366.","journal-title":"Md)"},{"issue":"7","key":"3627_CR54","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s12276-024-01268-1","volume":"56","author":"CM Lee","year":"2024","unstructured":"Lee CM, Hwang Y, Kim M, Park Y-C, Kim H, Fang S. PHGDH: a novel therapeutic target in cancer. Exp Mol Med. 2024;56(7):1513\u201322.","journal-title":"Exp Mol Med"},{"key":"3627_CR55","doi-asserted-by":"publisher","unstructured":"Pathria G, Scott DA, Feng Y, Sang Lee J, Fujita Y, Zhang G et al. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J. 2018;37(20).\u00a0https:\/\/doi.org\/10.15252\/embj.201899735.","DOI":"10.15252\/embj.201899735"},{"issue":"16","key":"3627_CR56","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1093\/nar\/gkt563","volume":"41","author":"W B\u2019Chir","year":"2013","unstructured":"B\u2019Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, et al. The eIF2\u03b1\/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 2013;41(16):7683\u201399.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"3627_CR57","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1158\/0008-5472.CAN-20-1541","volume":"81","author":"DC Montrose","year":"2021","unstructured":"Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XK, et al. Exogenous and endogenous sources of Serine contribute to colon cancer Metabolism, Growth, and resistance to 5-Fluorouracil. Cancer Res. 2021;81(9):2275\u201388.","journal-title":"Cancer Res"},{"key":"3627_CR58","doi-asserted-by":"publisher","first-page":"1200538","DOI":"10.3389\/fphar.2023.1200538","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang K, Lu H, Wang X, Liu Q, Hu J, Liu Y, et al. Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC. Front Pharmacol. 2023;14:1200538.","journal-title":"Front Pharmacol"},{"issue":"12","key":"3627_CR59","doi-asserted-by":"publisher","first-page":"109706","DOI":"10.1016\/j.celrep.2021.109706","volume":"36","author":"X Li","year":"2021","unstructured":"Li X, Gracilla D, Cai L, Zhang M, Yu X, Chen X, et al. ATF3 promotes the Serine synthesis pathway and tumor growth under dietary Serine restriction. Cell Rep. 2021;36(12):109706.","journal-title":"Cell Rep"},{"issue":"9","key":"3627_CR60","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/1878-0261.12697","volume":"14","author":"H Yoshino","year":"2020","unstructured":"Yoshino H, Enokida H, Osako Y, Nohata N, Yonemori M, Sugita S, et al. Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine\/cisplatin and the contribution of promoter DNA hypomethylation. Mol Oncol. 2020;14(9):2190\u2013202.","journal-title":"Mol Oncol"},{"issue":"8","key":"3627_CR61","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.trecan.2021.06.004","volume":"7","author":"A Buqu\u00e9","year":"2021","unstructured":"Buqu\u00e9 A, Galluzzi L, Montrose DC. Targeting Serine in cancer: is two better than one? Trends Cancer. 2021;7(8):668\u201370.","journal-title":"Trends Cancer"},{"key":"3627_CR62","doi-asserted-by":"publisher","first-page":"108488","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin J-J. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharmacol Ther. 2023;249:108488.","journal-title":"Pharmacol Ther"},{"key":"3627_CR63","doi-asserted-by":"publisher","first-page":"111824","DOI":"10.1016\/j.biopha.2021.111824","volume":"141","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, et al. New insight towards development of Paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother. 2021;141:111824.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3627_CR64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-019-1053-y","volume":"38","author":"X Ma","year":"2019","unstructured":"Ma X, Li B, Liu J, Fu Y, Luo Y. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. J Experimental Clin Cancer Research: CR. 2019;38(1):66.","journal-title":"J Experimental Clin Cancer Research: CR"},{"issue":"1","key":"3627_CR65","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7150\/ijbs.29203","volume":"15","author":"L Liao","year":"2019","unstructured":"Liao L, Ge M, Zhan Q, Huang R, Ji X, Liang X, et al. PSPH mediates the metastasis and proliferation of Non-small cell lung cancer through MAPK signaling pathways. Int J Biol Sci. 2019;15(1):183\u201394.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"3627_CR66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semcancer.2012.02.013","volume":"22","author":"N Tiwari","year":"2012","unstructured":"Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Sem Cancer Biol. 2012;22(3):194\u2013207.","journal-title":"Sem Cancer Biol"},{"issue":"7","key":"3627_CR67","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.3390\/ijms24076046","volume":"24","author":"KM da Costa","year":"2023","unstructured":"da Costa KM, Freire-de-Lima L, da Fonseca LM, Previato JO, Mendon\u00e7a-Previato L, Valente RDC. ABCB1 and ABCC1 function during TGF-\u03b2-Induced Epithelial-Mesenchymal transition: relationship between multidrug resistance and tumor progression. Int J Mol Sci. 2023;24(7):6046.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3627_CR68","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41467-023-36708-5","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang K, Luo L, Fu S, Wang M, Wang Z, Dong L, et al. PHGDH arginine methylation by PRMT1 promotes Serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat Commun. 2023;14(1):1011.","journal-title":"Nat Commun"},{"issue":"12","key":"3627_CR69","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1016\/j.ymthe.2024.10.025","volume":"32","author":"F-F Chan","year":"2024","unstructured":"Chan F-F, Kwan KK-L, Seoung D-H, Chin DW-C, Ng IO-L, Wong CC-L, et al. N6-Methyladenosine modification activates the Serine synthesis pathway to mediate therapeutic resistance in liver cancer. Mol Ther. 2024;32(12):4435\u201347.","journal-title":"Mol Ther"},{"issue":"1","key":"3627_CR70","doi-asserted-by":"publisher","first-page":"e22942","DOI":"10.1002\/jbt.22942","volume":"36","author":"T Liu","year":"2022","unstructured":"Liu T, Sun L, Zhang Y, Wang Y, Zheng J. Imbalanced GSH\/ROS and sequential cell death. J Biochem Mol Toxicol. 2022;36(1):e22942.","journal-title":"J Biochem Mol Toxicol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03627-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03627-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03627-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:04:14Z","timestamp":1770123854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03627-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3627"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03627-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved and licensed by the Animal Ethics Committee of Jiangxi University of Science and Technology (Y202451).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors confirm their consent to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}